Early profound secondary autoimmune thrombocytopenia induced by clopidogrel in a patient with a coronary artery stent.

Clopidogrel in combination with aspirin is commonly used for the prevention of thrombosis in patients with coronary artery stents [1]. moreover, since being introduced clopidogrel has proven to be very safe, tolerable, and efficacious [2]. Indications for clopidogrel use are expanding, and include reduction of such cardiovascular events as myocardial infarction and stroke in appropriate patients. As the use of clopidogrel increases, uncommon side effects are encountered more frequently [3]. Autoimmune thrombocytopenia is an extremely rare adverse effect of clopidogrel therapy [4]. We report a case of autoimmune thrombocytopenia related to standard clopidogrel treatment in a patient 2 days after coronary stenting.